Tatva Chintan Pharma Chem Limited (BOM:543321)
India · Delayed Price · Currency is INR 1,198.05
+16.60 (1.41%)
At close: Feb 13, 2026
Tatva Chintan Pharma Chem Income Statement
Financials in millions INR. Fiscal year is April - March.
Millions INR. Fiscal year is Apr - Mar.
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Dec '25 Dec 31, 2025 | Mar '25 Mar 31, 2025 | Mar '24 Mar 31, 2024 | Mar '23 Mar 31, 2023 | Mar '22 Mar 31, 2022 | Mar '21 Mar 31, 2021 |
Revenue | 4,796 | 3,827 | 3,935 | 4,236 | 4,336 | 3,004 |
Revenue Growth (YoY) | 28.53% | -2.74% | -7.11% | -2.31% | 44.38% | 14.10% |
Cost of Revenue | 2,331 | 2,060 | 1,830 | 2,327 | 2,015 | 1,574 |
Gross Profit | 2,465 | 1,767 | 2,105 | 1,910 | 2,321 | 1,430 |
Selling, General & Admin | 615.16 | 545.27 | 563.05 | 430.87 | 319.58 | 252.51 |
Other Operating Expenses | 1,113 | 878.78 | 848.1 | 798.39 | 915.23 | 508.18 |
Operating Expenses | 2,071 | 1,701 | 1,667 | 1,325 | 1,317 | 828.02 |
Operating Income | 393.72 | 66.82 | 437.83 | 584.69 | 1,005 | 601.81 |
Interest Expense | -14.07 | -8.96 | -61.51 | -79.97 | -43.51 | -39.85 |
Interest & Investment Income | 4.87 | 4.87 | 23.64 | 38.38 | 45.4 | 2.77 |
Currency Exchange Gain (Loss) | 12.45 | 12.45 | 28.15 | -72.9 | 38.41 | 37.53 |
Other Non Operating Income (Expenses) | 26.94 | 0.04 | 5.86 | 10.89 | -4.15 | 3.84 |
EBT Excluding Unusual Items | 423.91 | 75.22 | 433.97 | 481.09 | 1,041 | 606.1 |
Gain (Loss) on Sale of Investments | 0.75 | 0.75 | 1.89 | - | - | - |
Gain (Loss) on Sale of Assets | -1.18 | -1.18 | -1.48 | -0.01 | -0.51 | -0.34 |
Other Unusual Items | 1 | 1 | 1.62 | -35.43 | 0.73 | - |
Pretax Income | 424.48 | 75.79 | 436 | 445.65 | 1,041 | 605.76 |
Income Tax Expense | 96.85 | 18.66 | 132.46 | -9.22 | 82.47 | 83.14 |
Net Income | 327.63 | 57.13 | 303.54 | 454.87 | 958.74 | 522.62 |
Net Income to Common | 327.63 | 57.13 | 303.54 | 454.87 | 958.74 | 522.62 |
Net Income Growth | 129.16% | -81.18% | -33.27% | -52.55% | 83.45% | 38.30% |
Shares Outstanding (Basic) | 23 | 23 | 23 | 22 | 21 | 20 |
Shares Outstanding (Diluted) | 23 | 23 | 23 | 22 | 21 | 20 |
Shares Change (YoY) | -0.19% | 2.20% | 3.27% | 3.10% | 7.03% | - |
EPS (Basic) | 14.02 | 2.44 | 13.26 | 20.52 | 44.59 | 26.02 |
EPS (Diluted) | 14.02 | 2.44 | 13.26 | 20.52 | 44.59 | 26.02 |
EPS Growth | 129.60% | -81.60% | -35.38% | -53.98% | 71.39% | 38.32% |
Free Cash Flow | - | -516.01 | -304.71 | -1,753 | -689.27 | -12.74 |
Free Cash Flow Per Share | - | -22.06 | -13.31 | -79.10 | -32.06 | -0.63 |
Dividend Per Share | - | 1.000 | 2.000 | 2.000 | 2.000 | 5.000 |
Dividend Growth | - | -50.00% | - | - | -60.00% | 150.00% |
Gross Margin | 51.40% | 46.18% | 53.50% | 45.08% | 53.53% | 47.60% |
Operating Margin | 8.21% | 1.75% | 11.13% | 13.80% | 23.17% | 20.04% |
Profit Margin | 6.83% | 1.49% | 7.71% | 10.74% | 22.11% | 17.40% |
Free Cash Flow Margin | - | -13.48% | -7.74% | -41.39% | -15.90% | -0.42% |
EBITDA | 669.26 | 332.06 | 689.34 | 676.3 | 1,083 | 666.37 |
EBITDA Margin | 13.96% | 8.68% | 17.52% | 15.96% | 24.98% | 22.19% |
D&A For EBITDA | 275.54 | 265.24 | 251.51 | 91.61 | 78.45 | 64.56 |
EBIT | 393.72 | 66.82 | 437.83 | 584.69 | 1,005 | 601.81 |
EBIT Margin | 8.21% | 1.75% | 11.13% | 13.80% | 23.17% | 20.04% |
Effective Tax Rate | 22.82% | 24.62% | 30.38% | - | 7.92% | 13.73% |
Revenue as Reported | 4,846 | 3,850 | 4,010 | 4,294 | 4,427 | 3,056 |
Source: S&P Global Market Intelligence. Standard template. Financial Sources.